|
|
|---|
Oberbegriffe: Blastom,
Glioblastom,
Stoma
Unterbegriffe: Glioblastomas,
glioblastoma stem cells
Verwandte Begriffe: Bandstoma,
Glioblastom,
Glioblastoma,
Glioblastompatienten,
Sekundärblastome,
Stomadurchmesser,
Stomakanal,
Stomarückoperation,
Tracheostoma,
Urethrostoma,
Urethrostomas,
Ventrikulozisternostomiestoma,
Ventrikulozisternostomiestomas
|
1. Nakai K;
Yamamoto T;
Kumada H;
Matsumura A
Boron Neutron Capture Therapy for Glioblastoma: A Phase-I/II Clinical Trial at JRR-4
BNCT
European Association of NeuroOncology Magazine 2014; 4 (3): 116-123
Scheme of the Linac-based BNCT facility at the University of Tsukuba and
photographs of the installed equipment Keywords: BNCT,
scheme
|
|
|
2. Nakai K;
Yamamoto T;
Kumada H;
Matsumura A
Boron Neutron Capture Therapy for Glioblastoma: A Phase-I/II Clinical Trial at JRR-4
BNCT
European Association of NeuroOncology Magazine 2014; 4 (3): 116-123
Kaplan-Meyer survival curve of BNCT-treated patients (n = 16) with newly diagnosed
glioblastoma. Median overall survival of grade-IV patients was 22.3 months. Keywords: BNCT,
chart,
glioblastoma
|
|
|
3. Nakai K;
Yamamoto T;
Kumada H;
Matsumura A
Boron Neutron Capture Therapy for Glioblastoma: A Phase-I/II Clinical Trial at JRR-4
GBM patient
European Association of NeuroOncology Magazine 2014; 4 (3): 116-123
(a) Serial MRI image of the GBM patient treated with protocol IV. The scalp
was unremarkable. Hair loss continued for more than 1 year. (b) Recurrent GBM patient
who underwent BNCT after 60-Gy irradiation. The tumour was stable for more
than 3 years. Keywords: GBM,
glioblastoma,
MRI,
tumour
|
|
|
4. Nakai K;
Yamamoto T;
Kumada H;
Matsumura A
Boron Neutron Capture Therapy for Glioblastoma: A Phase-I/II Clinical Trial at JRR-4
BNCT
European Association of NeuroOncology Magazine 2014; 4 (3): 116-123
The concept of boron neutron capture therapy (BNCT). Keywords: BNCT,
boron neutron capture therapy
|
|
|
5. Schnell O
Impact of Molecular Markers on Personalised-Treatment Concepts in Gliomas
Glioblastoma
European Association of NeuroOncology Magazine 2014; 4 (3): 109-115
Possible genetic pathways in glioblastomas.
Glioblastomas can be differentiated into primary
GBM (de novo occurrence) or secondary GBM, which
originate from either a low-grade diffuse astrocytoma
(WHO grade II) directly or via malignant transformation
from an anaplastic astrocytoma WHO grade III.
It has been demonstrated that both GBM pathways
show genetic alterations at different time points and/
or in a different frequency. Some of them are shown
in this figure which was modified from the literature
[46]. Keywords: genetic pathway,
glioblastoma,
scheme
|
|
|
6. Schnell O
Impact of Molecular Markers on Personalised-Treatment Concepts in Gliomas
MGMT
European Association of NeuroOncology Magazine 2014; 4 (3): 109-115
Effect of MGMT promoter methylation status in glioblastomas. In GBM,
hypermethylation of the MGMT promoter results in reduction of MGMT protein, which
in turn leads to improved chemosensitivity for TMZ chemotherapy or combined radiochemotherapy.
Therefore, MGMT promoter methylation is correlated with improved
overall survival in these patients. In contrast, GBM patients with unmethylated MGMT
promoter status may have reduced response to radio-/chemotherapy and therefore
worse prognosis (mod from [1, 17]). Keywords: glioblastoma,
MGMT,
scheme
|
|
|
7. Götz I;
Grosu AL;
Spehl TS
Role of PET Imaging in Patients with High-Grade Gliomas undergoing anti-angiogenic Therapy with Bevacizumab – Review of the Literature and Case Report
Glioblastoma
European Association of NeuroOncology Magazine 2014; 4 (3): 102-108
Imaging results of a patient with glioblastoma undergoing bevacizumab
therapy. First column: MRI (MP-RAGE with contrast enhancement); second column:
18F-FET-PET (parametric images scaled to mean uptake in a right temporal reference
region); third column: image fusion. (A) scan prior to therapy 07/2010; (B) scan after
8 weeks of bevacizumab 09/2010; (C) scan after 16 weeks of bevacizumab 11/2010;
(D) scan after re-irradiation with 20 Gy, 01/2011. Bevacizumab therapy was continued.
For details, see text Keywords: Bevacizumab,
glioblastoma,
MRI
|
|
|
8. Uckermann O;
Galli R;
Mackenroth L;
Geiger K;
Steiner G;
Koch E;
Schackert G;
Kirsch M
Optical Biochemical Imaging: Potential New Applications in Neuro-Oncology
NLO imaging
European Association of NeuroOncology Magazine 2014; 4 (1): 20-26
Multimodal NLO imaging of human tumours (red: CARS, green: TPEF, blue: SHG), overlaid with the bright field images of the unstained sample. The technique allows to retrieve detailed morphochemical information about tissue structure and properties on unstained samples. (a) Cryosection of human glioblastoma (scale bar: 200 μm). (b) High magnification of the border between tumour and normal tissue as indicated in (a). (c) Cryosection of human neuroma (scale bar: 0.5 mm). Keywords: NLO imaging,
nonlinear optical microscopy
|
|
|
9. Uckermann O;
Galli R;
Mackenroth L;
Geiger K;
Steiner G;
Koch E;
Schackert G;
Kirsch M
Optical Biochemical Imaging: Potential New Applications in Neuro-Oncology
CARS image
European Association of NeuroOncology Magazine 2014; 4 (1): 20-26
CARS microscopy of infiltrative experimental
glioblastoma in a mouse model: The intensity of the CARS image and the morphological details permit to distinguish between the tumour mass, the infiltrative area, and the normal brain grey and white matters. H&E staining (top) CARS image (centre). The intensity of the CARS signal along the blue line is plotted in the graph (bottom). Mean intensity values for the different types of tissue are also reported. Mean intensity that characterizes the normal grey tissue is reduced to approximately 50 % in the infiltrative area and to approximately 30 % in the tumour. Lipid rich white matter is characterized by high CARS signal intensity (228, saturation in some areas). Keywords: CARS image,
scheme
|
|
|
10. Abacioglu U
Interview with Dr Michael Weller (Zurich) about the Phase-III EGFRvIII Vaccine Trial on Newly Diagnosed EGFRvIII-Positive Glioblastoma
ACT IV
European Association of NeuroOncology Magazine 2013; 3 (3): 155-156
Trial scheme Keywords: ACT IV,
scheme
|
|
|
11. Hamerlik P;
Rich JN;
Lathia JD
News and Views Basic Science: Glioblastoma Stem Cells
GSC
European Association of NeuroOncology Magazine 2013; 3 (2): 49-55
Glioblastoma stem cells (GSC) reside in vascular and hypoxic niches. Schematic
representation of GSC residing in a vascular niche supported by blood vessels
and hypoxic niche adjacent to necrotic regions. Each niche promotes the maintenance
of the GSC population and supports the expansion of the tumour mass. Keywords: glioblastoma stem cells,
scheme
|
|
|
12. Xu S;
Heimberger AB
Emerging Immune Therapeutics Targeting Glioblastoma-Mediated Immune Suppression: Dark Before the Dawn
Glioblastoma
European Association of NeuroOncology Magazine 2013; 3 (1): 15-22
Schema demonstrating immune activation and the role of
immune suppression and checkpoints. Glioblastoma exerts profound
immunosuppressive effects via multiple, redundant mechanisms, including
the TGF-β/VEGF signalling pathway, IL-2Rα/CD25-mediated IL-
2 deprivation, CTLA-4/PD-1/PD-L1 immune checkpoint interaction,
STAT3 activation, as well as by IDO/Arg-1 enzymatic suppression. All of
these mechanisms have been investigated as potential therapeutic targets
for glioblastoma treatment in various clinical and preclinical trials. Keywords: glioblastoma,
scheme
|
|
|
13. Proescholdt M;
Doenitz C;
Brawanski A
Surgery of Malignant Gliomas Using Modern Technology
Glioma - Surgery
European Association of NeuroOncology Magazine 2013; 3 (1): 11-14
Quantification of the preoperative tumour volume in malignant gliomas. (A) Axial T1-weighted MRI scan of a patient with a left frontal glioblastoma. (B) The
contrast-enhancing part of each section is outlined and subsequently fused to generate (C) a 3-dimensional segment which can be quantified volumetrically. Keywords: glioma,
MRI,
Tumor
|
|
|
14. Wohlgenannt V;
Oberndorfer S;
Grisold W
Intractable Headache in a Glioblastoma Patient
Glioblastoma
European Association of NeuroOncology Magazine 2012; 2 (3): 134-135
T1-weighted MRI (axial) with contrast media, showing enhancement of
the meninges (arrows), and only little enhancement at the primary tumour location
at the left temporobasal area (asterisk). Keywords: glioblastoma,
MRI
|
|
|
15. Wohlgenannt V;
Oberndorfer S;
Grisold W
Intractable Headache in a Glioblastoma Patient
Glioblastoma
European Association of NeuroOncology Magazine 2012; 2 (3): 134-135
T1-weighted MRI (sagittal) with contrast media, showing enhancement
of the meninges (arrows). Keywords: glioblastoma,
MRI
|
|
|
16. Pace A;
Villani V
Extra-Cranial Metastases from Glioblastoma Multiforme
Skeletal involvement
European Association of NeuroOncology Magazine 2012; 2 (2): 91-92
Radionuclide scan showing extensive skeletal involvement with diffuse
vertebral and iliac bilateral localizations. Keywords: radionuclide scan,
skeletal involvement
|
|
|
17. Pace A;
Villani V
Extra-Cranial Metastases from Glioblastoma Multiforme
Spine
European Association of NeuroOncology Magazine 2012; 2 (2): 91-92
Cervical spine T1-weighted MRI image with
gadolinium showing a mild leptomeningeal enhancement. Keywords: leptomeningeal enhancement,
MRI,
spine
|
|
|
18. Pace A;
Villani V
Extra-Cranial Metastases from Glioblastoma Multiforme
Spine
European Association of NeuroOncology Magazine 2012; 2 (2): 91-92
Spine T1-weighted MRI image with gadolinium.
The red arrow indicates the epidural tissue in the epidural space at the lumbosacral level. Keywords: lumbo-sacral level,
MRI,
spine
|
|
|
19. Pace A;
Villani V
Extra-Cranial Metastases from Glioblastoma Multiforme
Spine
European Association of NeuroOncology Magazine 2012; 2 (2): 91-92
Spine T1-weighted MRI image fat-sat
showing a diffuse signal alteration in the vertebral
bodies plus the presence of tissue at the
lumbo-sacral level. Keywords: lumbo-sacral level,
MRI,
spine
|
|
|
20. Weller M
Management of Gliomas: Relevance of Molecular Markers for Clinical Practice
Molecular markers in glioma
European Association of NeuroOncology Magazine 2012; 2 (1): 6-10
Molecular markers in glioma. A, 1p/19q co-deletion. Microsatellite-PCR-based analysis of allelic losses of 1p and 19q in an astrocytoma (WHO grade II) (A II) and
an anaplastic oligodendroglioma (WHO grade III) (AO III). Losses of both markers are indicated by arrowheads in AO III, but not A II. B, MGMT promoter methylation.
Methylation-specific PCR for unmethylated (U) and methylated (M) promoter sequences in 5 glioblastoma samples, including the glioblastoma cell line A172 as a positive
control for methylated and peripheral blood cells as a control for unmethylated promoter sequences, as well as water as a negative control (empty). C, IDH mutation. Grade-
II oligoastrocytoma, upper panels: HE staining, lower panels: IDH immunostaining, left panels: tumour centre, right panels: infiltration zone (Courtesy: Jörg Felsberg, Düsseldorf,
Germany). Reprinted from [2]. Keywords: glioma,
Marker,
Tumor
|
|
|
21. Skrzypek J;
Krause W
Sperm Cryopreservation in Cancer Patients
Tumor type
Journal für Reproduktionsmedizin und Endokrinologie - Journal of Reproductive Medicine and Endocrinology 2007; 4 (2): 106-108
Distribution of tumor type in 82 patients requiring cryopreservation. "Other tumors" comprise the following diagnoses: colon adenocarcinoma, anaplastic carcinoma (organ not known), cardiacarcinoma, Ewing sarcoma, glioblastoma, nephrosarcoma, medulloblastoma,
neuroectodermal tumor (without further classification), pancreatic carcinoma, phaeochromocytoma, prostate carcinoma. Keywords: cryopreservation,
Diagramm,
flowchart,
Kryopreservation,
Reproduktionsmedizin,
tumor type,
Tumortypus
|
|
|
| |
Suche Medizinische Publikationen
Suche Abbildungen und Grafiken
Medizinprodukte - Labortechnik
Antidotarium (Stand 2012)
Phytokodex (Stand 2012)
Fachbücher
Patientenliteratur
